Accuray Incorporated (ARAY)
Stock Price:
$2.59 USD
0.00 (0.00%)
Updated Aug 6, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
234.44M |
| Revenue (ttm) |
405.37M |
| Net Income (ttm) |
2.58M |
| Shares Out |
90.52M |
| EPS (ttm) |
0.02 |
| PE Ratio |
129.50 |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 6, 2020 |
| Last Price |
$2.59 |
| Previous Close |
$2.59 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
2.60 |
| Day's Range |
2.53 - 2.62 |
| Day's Volume |
291,648 |
| 52-Week Range |
1.33 - 4.68 |
More Stats
| Market Cap |
234.44M |
| Enterprise Value |
366.14M |
| Earnings Date (est) |
Aug 13, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
90.52M |
| Float |
82.62M |
| EPS (basic) |
0.02 |
| EPS (diluted) |
0.02 |
| FCF / Share |
-0.17 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
0.77% |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.17M |
| Short Ratio |
4.45 |
| Short % of Float |
3.42% |
| Beta |
2.03 |
| PE Ratio |
129.50 |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
0.58 |
| PB Ratio |
3.37 |
| Revenue |
405.37M |
| Operating Income |
10.57M |
| Net Income |
2.58M |
| Free Cash Flow |
-15.21M |
| Net Cash |
-131.71M |
| Net Cash / Share |
-1.46 |
| Gross Margin |
40.49% |
| Operating Margin |
2.61% |
| Profit Margin |
0.60% |
| FCF Margin |
-3.75% |
| ROA |
1.68% |
| ROE |
4.80% |
| ROIC |
1.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
1 |
Price Target
$7.00*
(170.27% upside)
Low
4.00
Current: $2.59
High
10.00
Target: 7.00
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 419 | 405 | 383 | 399 | 380 | 369 | 316 | 409 | 222 | 222 |
| Revenue Growth | 3.43% | 5.6% | -3.86% | 5% | 2.81% | 16.91% | -22.79% | 84.1% | 0.3% | - |
| Gross Profit | 163 | 162 | 141 | 159 | 145 | 143 | 97.64 | 137 | 107 | 104 |
| Operating Income | 0.58 | -3.80 | -9.82 | -4.87 | -19.17 | -18.14 | -92.86 | -56.23 | -27.83 | 2.84 |
| Net Income | -16.43 | -23.90 | -29.58 | -25.50 | -40.21 | -35.45 | -103 | -72.04 | -26.68 | 2.84 |
| Shares Outstanding | 87.47 | 84.89 | 82.50 | 80.51 | 78.28 | 75.80 | 73.28 | 70.89 | 60.09 | 57.56 |
| Earnings Per Share | -0.19 | -0.28 | -0.36 | -0.32 | -0.51 | -0.47 | -1.41 | -1.02 | -0.44 | 0.05 |
| Operating Cash Flow | -29.64 | 18.33 | -0.38 | 30.93 | -14.41 | 0.35 | -66.18 | -38.28 | 12.40 | -5.07 |
| Capital Expenditures | -4.31 | -6.28 | -5.03 | -8.07 | -10.45 | -11.93 | -15.13 | -10.77 | -4.02 | -5.13 |
| Free Cash Flow | -33.95 | 12.06 | -5.41 | 22.86 | -24.85 | -11.59 | -81.30 | -49.05 | 8.38 | -10.20 |
| Cash & Equivalents | 88.18 | 93.53 | 109 | 169 | 148 | 173 | 177 | 145 | 99.08 | 145 |
| Total Debt | 160 | 131 | 165 | 210 | 200 | 196 | 199 | 79.47 | - | - |
| Net Cash / Debt | -71.67 | -37.54 | -55.43 | -41.04 | -52.06 | -22.22 | -21.64 | 65.60 | 99.08 | 145 |
| Assets | 438 | 379 | 406 | 469 | 467 | 495 | 476 | 473 | 456 | 263 |
| Liabilities | 388 | 330 | 360 | 409 | 391 | 397 | 369 | 269 | 215 | 93.11 |
| Book Value | 49.87 | 48.63 | 46.53 | 59.66 | 75.78 | 98.55 | 107 | 196 | 230 | 170 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Accuray Incorporated |
| Country |
United States |
| Employees |
947 |
| CEO |
Joshua H. Levine |
Stock Information
| Ticker Symbol |
ARAY |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: ARAY |
| IPO Date |
February 8, 2007 |
Description
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.